Abstract
No public abstract is available from the verified source records.
Mohamed A. Hammad, Hossam M. Ashour
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Tissue-specific silencing of synthetic mRNAs by de-targeting elements maps vaccination-competent tissues and allows Cas9 de-immunization
10.1016/j.ymthe.2026.07.050 · 2026
mRNA vaccines—a new era in vaccinology
10.1038/nrd.2017.243 · 2018
Biodistribution of RNA vaccines and of their products: evidence from human and animal studies
10.3390/biomedicines12010059 · 2023
Lipid self-assembling nanoparticles as a novel platform for mRNA-based vaccination
10.1016/j.omtn.2026.102851 · 2026
Ionizable lipid nanoparticles of mRNA vaccines elicit NF-kappaB and IRF responses through toll-like receptor 4
10.1038/s41541-025-01124-x · 2025
Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV
10.1038/mt.2014.177 · 2015
Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery
10.1038/s41596-022-00755-x · 2023
Prevalence of preexisting antibodies to CRISPR-associated nuclease Cas9 in the USA population
10.1016/j.omtm.2018.06.006 · 2018
AAV-CRISPR gene editing is negated by pre-existing immunity to Cas9
10.1016/j.ymthe.2020.04.017 · 2020
Rational engineering of minimally immunogenic nucleases for gene therapy
10.1038/s41467-024-55522-1 · 2025
No additional external references are available.